BHVN vs HRMY
BHVN: Biohaven is a clinical-stage biopharmaceutical company developing innovative therapies for immunology, neurological disorders, and metabolic diseases using proprietary protein degradation and ion channel platforms. HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders.
Side-by-side fundamentals
| Metric | BHVN | HRMY | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $14.75 | $34.86 | |
| Market cap as of 2026-07-23 | $2.3B | $2.0B | |
| P/E as of 2026-07-23 | n/a | 13.86 | |
| PEG as of 2026-07-23 | n/a | 0.20 | |
| Net margin as of 2026-07-23 | n/a | +16.2% | |
| Gross margin as of 2026-07-23 | n/a | +76.5% | |
| Operating margin as of 2026-07-23 | n/a | +21.1% | |
| ROE as of 2026-07-23 | -450.0% | +17.2% | HRMY higher |
| ROA as of 2026-07-23 | -138.0% | +12.0% | HRMY higher |
| Debt / equity as of 2026-07-23 | 1.87 | 0.17 | HRMY lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +20.7% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +25.6% | |
| Beta as of 2026-07-23 | 2.98 | 0.91 | |
| 1-year return as of 2026-07-22 close | +12.3% | +4.5% | BHVN higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.